201 related articles for article (PubMed ID: 15001337)
1. Ximelagatran or warfarin in atrial fibrillation?
MacAllister R; Hingorani AD; Casas JP
Lancet; 2004 Feb; 363(9410):735-6; author reply 736. PubMed ID: 15001337
[No Abstract] [Full Text] [Related]
2. Ximelagatran or warfarin in atrial fibrillation?
Eikelboom J; Hankey G
Lancet; 2004 Feb; 363(9410):734; author reply 734, 736. PubMed ID: 15001334
[No Abstract] [Full Text] [Related]
3. Ximelagatran or warfarin in atrial fibrillation?
Stöllberger C; Finsterer J
Lancet; 2004 Feb; 363(9410):734-5; author reply 736. PubMed ID: 15001336
[No Abstract] [Full Text] [Related]
4. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Selçuk H; Selçuk MT; Maden O
Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
[TBL] [Abstract][Full Text] [Related]
5. Ximelagatran or warfarin in atrial fibrillation?
Epstein EF
Lancet; 2004 Feb; 363(9410):736; author reply 736. PubMed ID: 15001338
[No Abstract] [Full Text] [Related]
6. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
[TBL] [Abstract][Full Text] [Related]
7. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
Akins PT; Feldman HA; Zoble RG; Newman D; Spitzer SG; Diener HC; Albers GW
Stroke; 2007 Mar; 38(3):874-80. PubMed ID: 17255547
[TBL] [Abstract][Full Text] [Related]
8. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
O'Brien CL; Gage BF
JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
[TBL] [Abstract][Full Text] [Related]
9. Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis.
Berry C; Norrie J; McMurray JJ
Cardiovasc Drugs Ther; 2005 Mar; 19(2):149-51. PubMed ID: 16025234
[TBL] [Abstract][Full Text] [Related]
10. [SPORTIF III and V trials: a major breakthrough for long-term oral anticoagulation].
Kulbertus H
Rev Med Liege; 2003 Dec; 58(12):770-3. PubMed ID: 14978854
[TBL] [Abstract][Full Text] [Related]
11. [Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Cavuşoğlu Y
Anadolu Kardiyol Derg; 2007 Jun; 7(2):217-8; author reply 218-9. PubMed ID: 17513231
[No Abstract] [Full Text] [Related]
12. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
Diener HC;
Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
[TBL] [Abstract][Full Text] [Related]
13. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
Albers GW;
Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulation for atrial fibrillation in the elderly.
Halperin JL
Am J Geriatr Cardiol; 2005; 14(2):81-6. PubMed ID: 15785149
[TBL] [Abstract][Full Text] [Related]
15. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
[TBL] [Abstract][Full Text] [Related]
16. New possibilities in anticoagulant management of atrial fibrillation.
Waldo AL
Rev Cardiovasc Med; 2004; 5 Suppl 5():S30-8. PubMed ID: 15619613
[TBL] [Abstract][Full Text] [Related]
17. [New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins].
Scardi S; Giansante C
Ital Heart J Suppl; 2004 Sep; 5(9):705-11. PubMed ID: 15568608
[TBL] [Abstract][Full Text] [Related]
18. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Tandoğan I
Anadolu Kardiyol Derg; 2007 Jun; 7(2):216; author reply 218-9. PubMed ID: 17513230
[No Abstract] [Full Text] [Related]
19. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Kiraç FS
Anadolu Kardiyol Derg; 2007 Jun; 7(2):214-5; author reply 218-9. PubMed ID: 17513229
[No Abstract] [Full Text] [Related]
20. Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials.
Cleland JG; Shelton R; Nikitin N; Ford S; Frison L; Grind M
Eur J Heart Fail; 2007; 9(6-7):730-9. PubMed ID: 17360232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
